Sociedad Americana de Hirudoterapia

Medicines Control Authority of Zimbabwe

MCAZ · Zimbabwe · africa

Regulatory jurisdiction profileJurisdictional reference
Unregulatednational regulator

Zimbabwe's Medicines Control Authority — leech-specific regulatory pathway has not been independently verified by ASH; medicinal leeches fall under the general national pharmaceutical and medical device framework as appropriate.

Regulatory Profile

Agency type
national regulator
Region
africa
Country
Zimbabwe
Leech status
unregulated
Last ASH review
2026-05-27

Relevant Regulation Codes

  • Zimbabwean Medicines and Allied Substances Control Act [Chapter 15:03]
  • Zimbabwean national medical device regulatory framework
  • African Medicines Agency (AMA) harmonised frameworks (where applicable)

Prescriber Requirements

  • Medical and Dental Practitioners Council of Zimbabwe–registered physician — order required for any biomedical device application
  • Allied health professional application under physician supervision per institutional protocol

Supply Chain & GMP

MCAZ registration as applicable; English-language labelling. Standard cold-chain conditions, with logistical constraints typical of the contemporary Zimbabwean economic environment.

Import/Export Rules

MCAZ and Department of Veterinary Services clearance for live invertebrates; CITES Appendix II paperwork for Hirudo medicinalis / verbana.

Reimbursement Context

Zimbabwean public health system coverage depends on inpatient bundling; outpatient hirudotherapy is generally not separately reimbursed.

ASH Editorial Notes

Leech-specific pathway not independently verified by ASH; falls under general medical device / traditional medicine framework as appropriate. Sub-Saharan African regulatory frameworks are progressively coordinating through the African Medicines Agency (AMA); whether this captures live-organism medical devices has not been independently mapped by ASH.

Related Jurisdictions

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.